NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD

Nature Reviews Gastroenterology and Hepatology

Volumn 12, Issue 2, 2015, Pages 65-66

  Rinella, Mary E ^a   Sanyal, Arun J ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; BILE ACID; FARNESOID X RECEPTOR; GADOXETIC ACID; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OBETICHOLIC ACID; PLACEBO; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; 6-ETHYLCHENODEOXYCHOLIC ACID; CHENODEOXYCHOLIC ACID; HYPOCHOLESTEROLEMIC AGENT; MEMBRANE PROTEIN; TM6SF2 PROTEIN, HUMAN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL SYNTHESIS; CLINICAL FEATURE; CONTRAST ENHANCEMENT; DISEASE ASSOCIATION; DISEASE COURSE; GENE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PATHOGENESIS; PNPLA3 GENE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TM6SF2 GENE; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; COMPLICATION; GENETICS; LIVER NEOPLASMS; NON-ALCOHOLIC FATTY LIVER DISEASE;

ANTICHOLESTEREMIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHENODEOXYCHOLIC ACID; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER NEOPLASMS; MEMBRANE PROTEINS; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84961354544     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2014.232     Document Type: Review

References (10)

1. Neuschwander-Tetri, B. A. et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 52, 913-924 (2010).
2. Loomba, R. & Sanyal, A. J. The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 10, 686-690 (2013).
3. Dunn, W. et al. Suspected nonalcoholic fatty liver disease and mortality risk in a populationbased cohort study. Am. J. Gastroenterol. 103, 2263-2271 (2008).
4. Siddiqui, M. S. et al. Severity of nonalcoholic fatty liver disease and progression to cirrhosis associate with atherogenic lipoprotein profile. Clin. Gastroenterol. Hepatol. http://dx.doi.org/10.1016/j.cgh.2014.10.008.
5. Rosenson, R. S., Otvos, J. D. & Freedman, D. S. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am. J. Cardiol. 90, 89-94 (2002).
6. Kozlitina, J. et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 46, 352-356 (2014).
7. Mittal, S. & El-Serag, H. B. Epidemiology of hepatocellular carcinoma: consider the population. J. Clin. Gastroenterol. 47 (Suppl.), S2-S6 (2013).
8. Wong, R. J., Cheung, R. & Ahmed, A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 59, 2188-2195 (2014).
9. Bastati, N. et al. Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study. Radiology 271, 739-747 (2014).
10. Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(14)61933-4.